VILNIUS, Lithuania–(BUSINESS WIRE)–Biomatter, the custom enzyme design company, today announced the closing of an oversubscribed $18 million Series A financing led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet. Biomatter’s work is already in products, including Thermo Fisher Scientific’s Invitrogen™ SuperScript™ V Reverse Transcriptase, an enzyme used to convert RNA into DNA in molecular biology labs and mRNA research. Biomatter collaborated wi
